Serum transferrin as a predictor of prognosis for hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma.
Serum transferrin as a predictor of prognosis for hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma.
复制标题
血清转铁蛋白作为晚期肝细胞癌肝动脉灌注化疗预后的预测因子。
作者：
Hidenori Shiraha;Junro Kataoka;Shinichiro Nakamura;Kazuhiro Nouso;Shigeru Horiguchi;et.al.;吉田雄一 木曽真一 竹原徹郎;Zaitu J
AimWe 最近报道铁螯合剂去铁胺 (DFO) 对晚期肝细胞癌 (HCC) 患者有效。因此，铁调节可能对 HCC 治疗产生重要影响。由于转铁蛋白是调节铁稳态的天然螯合剂，因此它可能以与 DFO 类似的方式发挥抗癌剂的作用。本研究的目的是评估血清转铁蛋白作为接受肝动脉灌注化疗 (HAIC) 的晚期 HCC 患者的预后预测因子。方法我们回顾性研究了 44 例接受 HAIC 的患者，并分析了其可能用作预后预测因子的各种参数。结果1 年、2 年和 3 年累积生存率分别为 36.4%、18.2% 和 8.5%，中位生存时间（MST）为 7.0 个月。血清转铁蛋白≥190mg/dL（MST，12.0个月）的患者生存率明显优于血清转铁蛋白低于190mg/dL（MST，4.9个月）的患者。多变量分析确定血清转铁蛋白为 190 mg/dL 或更高（风险比 [HR]，0.282；95% 置信区间 [CI]，0.132–0.603；P= 0.001）和 Child–Pugh 评分 B（HR，1.956；95% CI， 1.034–3.700；P= 0.039）作为独立的预后预测因子。血清转铁蛋白水平与治疗效果存在显着相关性(P<0.001)。结论血清转铁蛋白可作为晚期HCC患者HAIC治疗前的预后预测指标。
AimWe recently reported that the iron chelator deferoxamine (DFO) is efficacious in advanced hepatocellular carcinoma (HCC) patients. Iron regulation may thus have an important impact in HCC therapy. Because transferrin is a native chelator that regulates iron homeostasis, it may act as an anticancer agent in a similar manner as DFO. The objective of this study was to evaluate serum transferrin as a prognostic predictor in advanced HCC patients undergoing hepatic arterial infusion chemotherapy (HAIC).MethodsWe retrospectively studied 44 patients receiving HAIC and analyzed various parameters for their possible use as prognostic predictors.ResultsThe 1‐, 2‐ and 3‐year cumulative survival rates were 36.4%, 18.2% and 8.5%, respectively, and the median survival time (MST) was 7.0 months. The survival rates of patients who had serum transferrin of 190 mg/dL or more (MST, 12.0 months) were significantly better than those of patients who had serum transferrin of less than 190 mg/dL (MST, 4.9 months). Multivariate analysis identified serum transferrin of 190 mg/dL or more (hazard ratio [HR], 0.282; 95% confidence interval [CI], 0.132–0.603;P= 0.001) and Child–Pugh score B (HR, 1.956; 95% CI, 1.034–3.700;P= 0.039) as independent prognostic predictors. There was a significant correlation between serum transferrin level and therapeutic effect (P< 0.001).ConclusionSerum transferrin could be useful as a prognostic predictor in advanced HCC patients before HAIC treatment.